Diagnosis-to-Treatment Interval Reflects Clinical Urgency and Disease Burden in T-Lymphoblastic Lymphoma: A Multicenter Cohort Study
Open Access
- 19 August 2026
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6408
Abstract
Objective: Diagnosis-to-treatment interval (DTI) has been investigated in several lymphoma subtypes, but its significance in T-lymphoblastic lymphoma (T-LBL) remains unclear. We evaluated whether DTI reflects clinical urgency, disease burden and early outcomes in newly diagnosed T-LBL. Methods: We retrospectively analyzed 220 patients with newly diagnosed, mass-dominant, and histologically diagnosed T-LBL treated at four centers between 2003 and 2025. DTI was operationally defined as the interval from diagnostic biopsy to first systemic anti-lymphoma therapy and was primarily analyzed as a continuous variable per 7-day increase. Descriptive DTI groups were <15, 15–29 and ≥30 days. Results: Median DTI was 20 days (interquartile range [IQR], 14–32). Shorter DTI was associated with advanced stage, elevated lactate dehydrogenase (LDH), multiple extranodal involvement, central nervous system (CNS) involvement, B symptoms, lower hemoglobin and higher International Prognostic Index (IPI) score. CNS involvement remained independently associated with DTI < 15 days. In adjusted analyses, each 7-day increase in DTI was associated with lower odds of early treatment failure within 2 years (odds ratio [OR] 0.72, 95% confidence interval [CI] 0.58–0.88), lower hazards of progression-free survival (PFS) events (hazard ratio [HR] 0.84, 95% CI 0.74–0.94) and lower mortality (HR 0.84, 95% CI 0.73–0.98), but not complete response. Conclusions: Shorter DTI appears to reflect clinical urgency and disease burden rather than a causal effect of early treatment.Keywords
Funding Information
- National Natural Science Foundation of China (82300214)
- National Natural Science Foundation of China (82270195)
- Peking University Cancer Hospital (PY202312)
This publication has 25 references indexed in Scilit:
- Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphomaAnnals of Hematology, 2026
- Impact of diagnosis-to-treatment interval in relapsed or refractory diffuse large B-cell lymphomaInternational Journal of Hematology, 2026
- Time to diagnosis and treatment in lymphoma and implications for health-related outcomes: a systematic reviewLeukemia & Lymphoma, 2025
- DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell LymphomasClinical Lymphoma Myeloma and Leukemia, 2024
- Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphomaScientific Reports, 2021
- Outcome of adult T-lymphoblastic lymphoma depends on ALL-type chemotherapy, prognostic factors, and performance of allogeneic hematopoietic stem cell transplantationMedicine, 2018
- Time to treatment is an independent prognostic factor in aggressive non‐Hodgkin lymphomasBritish Journal of Haematology, 2018
- Adult T-type lymphoblastic lymphoma: Treatment advances and prognostic indicatorsExperimental Hematology, 2017
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemiaBlood, 2002